Literature DB >> 7991292

The antibiotic susceptibilities of Xanthomonas maltophilia and their relation to clinical management.

W J Smit1, A L Boquest, J E Geddes, F A Tosolini.   

Abstract

An increase in recovery of Xanthomonas maltophilia from clinical specimens at our institutions prompted, amongst other measures, an investigation of the antibiotic susceptibility patterns of the organism. Fifty-five consecutive first isolates of Xanthomonas maltophilia were obtained and antimicrobial susceptibility tests were carried out by the agar dilution method. Trimethoprim/sulfamethoxazole was the most active antimicrobial agent (94% susceptible), with 71% susceptible to ticarcillin/clavulanic acid, 56% susceptible to ciprofloxacin and 49% susceptible to ceftazidime. Amoxycillin/clavulanic acid and imipenem were inactive (0% susceptible), while aminoglycosides were effective against only 7% of isolates. Potentiation was observed with both the combination of trimethoprim and sulfamethoxazole and the combination of ticarcillin and clavulanic acid. Familiarity with the antibiotic susceptibility pattern of Xanthomonas maltophilia as well as the potential shortcomings of the in vitro susceptibility data are important in the effective clinical management of Xanthomonas maltophilia infections.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7991292     DOI: 10.1080/00313029400169751

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  7 in total

1.  Multiple antibiotic resistance in Stenotrophomonas maltophilia.

Authors:  A Alonso; J L Martínez
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

Review 2.  Imipenem/cilastatin: an update of its antibacterial activity, pharmacokinetics and therapeutic efficacy in the treatment of serious infections.

Authors:  J A Balfour; H M Bryson; R N Brogden
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

3.  Occurrence of variants with temperature-dependent susceptibility (TDS) to antibiotics among Stenotrophomonas maltophilia clinical strains.

Authors:  P Hejnar; M Kolár; V Hájek; D Koukalová; P Hamal
Journal:  Folia Microbiol (Praha)       Date:  2001       Impact factor: 2.099

Review 4.  Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia.

Authors:  M Denton; K G Kerr
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

5.  In vitro activities of beta-lactam-beta-lactamase inhibitor combinations against Stenotrophomonas maltophilia: correlation between methods for testing inhibitory activity, time-kill curves, and bactericidal activity.

Authors:  J L Muñoz Bellido; S Muñoz Criado; I García García; M A Alonso Manzanares; M N Gutiérrez Zufiaurre; J A García-Rodríguez
Journal:  Antimicrob Agents Chemother       Date:  1997-12       Impact factor: 5.191

6.  Novel nosocomial infections by Stenotrophomonas maltophilia: first reported case from Lucknow, North India.

Authors:  Chiranjoy Mukhopadhyay; Anudita Bhargava; Archana Ayyagari
Journal:  J Clin Microbiol       Date:  2003-08       Impact factor: 5.948

7.  Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: an increasing problem.

Authors:  Asma Marzouq Al-Jasser
Journal:  Ann Clin Microbiol Antimicrob       Date:  2006-09-18       Impact factor: 3.944

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.